Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

Arkansas court boots $1.2B J&J verdict on technical grounds

In defending the largest state-level decision ever won against Johnson & Johnson for its Risperdal marketing, the state of Arkansas said the New-Jersey based company didn't properly communicate the antipsychotic's risks and marketed it for off-label use. In its appeal, J&J said it didn't commit fraud or harm the state's Medicaid program. But Arkansas' Supreme Court had something entirely different to say when it overturned the $1.2 billion judgment Thursday.

J&J blazes a new pharma trail with industry's first designer-in-chief

Johnson & Johnson has designs on a brand-new way of thinking about products. The company is hiring a chief design officer, The Wall Street Journal reports, to create drugs and consumer products that look good, work well, and--it hopes--sell better.

J&J trumpets early success for 3-month Invega Sustenna PhIII schizophrenia trial

J&J wrapped a Phase III study of a 3-month formulation of Invega Sustenna early after an independent monitoring group called it on positive efficacy data. That's good news for J&J as well as Alkermes, which provided their NanoCrystal delivery tech for the new-and-improved therapy.

Don't bet on a home-run drug launch, even for power-hitting drugs

Two-thirds of new drugs fall short of expectations their first year on the market and continue to fall short after that. But McKinsey & Co. consultants found that good launches are very, very good. What makes the difference? The consulting firm took a close look at 60 different drug launches to find out.

McKinsey's 4 drug launch flavors: Good, bad, ugly and misguided

What's the probability of a good drug launch? About one in three, according to a new McKinsey & Co. analysis. And if a launch is good, it tends to be very, very good, beating forecasts year after year.

J&J's $2.5B-plus metal hip settlement offer approaches April 1 deadline

Patients have until April 1 to decide whether to sign on to the $2.5 billion-plus agreement Johnson & Johnson proposed last November to resolve 8,000 patient lawsuits involving defective all-metal hip implants. It's not clear yet whether the conglomerate will draw in enough people so the settlement can move forward.

J&J, Pharmacyclics and the future of Big Pharma dealmaking

Eventual winner Johnson & Johnson wasn't Pharmacyclics' first choice to partner with on ibrutinib, CEO Robert Duggan told FierceBiotech in January, but, as The Wall Street Journal lays out, J&J and its expansive approach to dealmaking won out in the end.

GlaxoSmithKline's FDA batting average tops the industry; Lilly, not so much

Reaping the benefits of deep-seated R&D reorganization, GlaxoSmithKline had the industry's best 6-year run of FDA nods for new drugs, according to EvaluatePharma, leading its competitors by a wide margin and leaving approval-starved outfits like Eli Lilly and Merck in the dust.

In SGLT2 diabetes fight, Lilly's empagliflozin loss is J&J and AstraZeneca's gain

Johnson & Johnson and AstraZeneca will just have to duke it out for share of the market for SGLT2 treatments for diabetes. A potential third competitor from Eli Lilly and Boehringer Ingelheim, empagliflozin, failed to win FDA approval, thanks to problems at a Boehringer manufacturing plant.

Word of a $16M Coloplast vaginal-mesh settlement spurs global resolution talk

Danish medical device maker Coloplast is said to have paid $16 million to settle lawsuits claiming it injured women with vaginal-mesh inserts. With settlement talk swirling around at least 5 more makers of the plagued devices, that has some watchers saying the time may be ripe for a global settlement.